MUC16 and idiopathic pulmonary fibrosis: Serum levels of extracellular MUC16 (CA-125) have been also identified as a biomarker for disease progression and death in IPF patients [19,20], as well as associated with the severity and risk of cancer in ILD patients [21,22].